Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Location status: Recruiting
NCT Number: NCT03710928
Despite major technological advances, management of type one diabetes mellitus (T1D) remains suboptimal, putting millions of people at risk for immediate and long-term complications. After meals, a mismatch between carbohydrate absorption rate and insulin action typically leads to alternating periods of hyper- and hypoglycemia. A conceptually promising approach to control both problems is dietary carbohydrate restriction to reduce postprandial blood glucose changes and insulin needs. In a prior survey study, the investigators documented exceptional glycemic control (HbA1c 5.67%) and low acute complication rates among 316 children and adults with T1D consuming a very-low-carbohydrate diet.
To test the feasibility of this approach, the investigators will conduct a randomized-controlled feeding study involving 32 adults and adolescents with T1D. Participants will be randomized to receive a very low carbohydrate vs. standard carbohydrate diet. Participants will be in the study for 12 weeks and receive all their meals by meal delivery.They will share continuous glucose monitoring data with the study team and be in close communication to adjust insulin doses as needed. All participants will have a screening visit, an individual or group education session, and 3 study visits to evaluate diabetes control and metabolic health. Some of these visits will have a fasting blood draw. Two of the visits will also comprise additional metabolic studies to assess glucagon response and brain function during hypoglycemia by magnetic resonance imaging (MRI). Participants will have IV catheters placed and receive IV insulin to drop blood glucose levels to 50 mg/dl for up to 30 minutes. The primary outcome will be HbA1c change from baseline. Secondary outcomes include detailed measures of glycemic variability, metabolic health, and quality of life.
Interested in participating?
Request Info18 year–40 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02115, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.
The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein.
All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.
The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein.
Time frame: 12 weeks - baseline
HbA1C change from baseline at 12 weeks will be compared between the 2 interventions
Time frame: week 0 and 12
average daily insulin dose over 1 week will be calculated
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated from 1-week continuous glucose monitoring data
Time frame: week 0 and 12
will be calculated by dividing blood glucose standard deviation by blood glucose average
Time frame: week 0 and 12
will be calculated by dividing blood glucose standard deviation by blood glucose average
Time frame: week 0 and 12
from venous blood
Time frame: week 0 and 12
from venous blood
Time frame: week 0 and 12
from venous blood
Time frame: week 0 and 12
from venous blood
Time frame: weeks 0, 1, 2, 4, 6, 9, 12
from venous blood and/or point-of-care testing
Time frame: week 0 and 12
from venous blood
Time frame: week 0, 6, and 12
The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.
Time frame: week 0, 6, and 12
BDI-II less suicidality is a 20-item self-report inventory that measures assesses for presence and severity of depression depressive symptoms. Each item is scored between 0-3. Item scores are added up to a total score (max. 60) and reported.
Time frame: week 0, 6, and 12
Assesses indicators of addictive-like eating.The YFAS includes two scoring options: 1) a "symptom count" that reflects the number of addiction-like criteria endorsed and 2) a dichotomous "diagnosis" that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met. The diagnosis score will be calculated at baseline and used as an effect modifier. Symptom counts will be reported separately as a longitudinal measure.
Time frame: Baseline, daily on days 1-7, then weekly; primary focus on change from baseline to day 7
Assesses withdrawal-type symptoms that may occur when individuals cut down on rewarding foods.
Contact information is provided by the study sponsor or research team.
Boston Children's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04219709
Acid-Base Imbalance, Acidosis
Boston, Massachusetts, United States
View Trial DetailsNCT04200391
Acid-Base Imbalance, Acidosis
Boston, Massachusetts, United States
View Trial DetailsNCT07056699
Type1diabetes
San Antonio, Texas, United States
View Trial DetailsNCT07522866
Type1diabetes
Atlanta, Georgia, United States
View Trial Details